Posology : מינונים

4.2 Posology and method of administration
The recommended dose of Rasilez is 150 mg once daily. In patients whose blood pressure is not adequately controlled, the dose may be increased to 300 mg once daily.
The antihypertensive effect is substantially present within two weeks (85-90%) after initiating therapy with 150 mg once daily.
Rasilez may be used alone or in combination with other antihypertensive agents. It must not be used in combination with Angiotensin Converting Enzyme Inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARB) in patients with diabetes mellitus.
Rasilez should be taken with a light meal once a day, preferably at the same time each day. Grapefruit juice should not be taken together with Rasilez.


RAS API JUN15 CL V10                                    REF CDS 6May14 & 18Dec14 Renal impairment
No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see sections 4.4 and 5.2). Rasilez is not recommended in patients with severe renal impairment (GFR < 30 mL/min/1.73m2).

Hepatic impairment
No adjustment of the initial dose is required for patients with mild to severe hepatic impairment (see section 5.2).

Elderly patients (over 65 years)
No adjustment of the initial dose is required for elderly patients.

Pediatric patients (below 18 years of age)
Rasilez is contraindicated in children less than 2 years of age (see sections 4.3, 4.4 and 5.3). Rasilez should not be used in children aged 2 to less than 6 years of age because of safety concern for potential aliskiren overexposure (see sections 4.4, 5 and 4.3) Limited data are available in children 6 to less than 18 years of age and the safety and efficacy of Rasilez has not been established in this age group. Use of Rasilez is not recommended in this population.